title: Combined intervention for the tertiary prevention of type 1 diabetes.
abstract: Recently published paper by Haller and coworkers in Journal of Clinical Investigation reported that a combination of low-dose anti-thymocyte globulin (ATG) and pegylated granulocyte-colony stimulating factor (G-CSF) may preserve β-cell function in patients with established type 1 diabetes.
authors.affiliation: Diabetes Center Shin-Koga Hospital Kurume Japan.
authors.forename: Eiji
authors.initials: E
authors.lastname: Kawasaki
mesh_terms: D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D050417:Insulin-Secreting Cells / Q000187:drug effects; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000961:Antilymphocyte Serum; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D011092:Polyethylene Glycols; C423652:pegylated granulocyte colony-stimulating factor